A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

A Phase 1 Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.

Inclusion Criteria:

• NSCLC who are eligible to receive a 6 week course of RT
• Part 1 - not candidates for definitive RT
• Part 2 - candidates for definitive RT

Exclusion Criteria:

• Severe COPD, pulmonary infection or interstitial pneumonitis
• Recent cellulitis
• Autoimmune disease